Perspective Therapeutics, Inc. (NYSE:CATX – Get Free Report) has been assigned an average recommendation of “Buy” from the seven analysts that are presently covering the company, Marketbeat reports. Seven investment analysts have rated the stock with a buy recommendation. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $20.00.
CATX has been the subject of several recent research reports. B. Riley increased their price objective on shares of Perspective Therapeutics from $12.00 to $17.00 and gave the stock a “buy” rating in a research report on Tuesday, April 9th. Cantor Fitzgerald reissued an “overweight” rating on shares of Perspective Therapeutics in a research report on Tuesday, June 25th. Bank of America initiated coverage on shares of Perspective Therapeutics in a research report on Thursday, July 25th. They issued a “buy” rating and a $24.00 price objective for the company. Royal Bank of Canada reissued an “outperform” rating and issued a $30.00 price objective on shares of Perspective Therapeutics in a research report on Friday, June 14th. Finally, Lifesci Capital reissued an “outperform” rating on shares of Perspective Therapeutics in a research report on Monday, May 6th.
Insider Activity
Institutional Inflows and Outflows
Large investors have recently added to or reduced their stakes in the stock. Rhumbline Advisers bought a new position in shares of Perspective Therapeutics in the 2nd quarter worth about $630,000. Bank of New York Mellon Corp lifted its position in shares of Perspective Therapeutics by 214.0% in the 2nd quarter. Bank of New York Mellon Corp now owns 137,268 shares of the company’s stock worth $1,369,000 after buying an additional 93,548 shares during the last quarter. Virtu Financial LLC bought a new position in shares of Perspective Therapeutics in the 1st quarter worth about $138,000. Janus Henderson Group PLC bought a new position in shares of Perspective Therapeutics in the 1st quarter worth about $15,511,000. Finally, Affinity Asset Advisors LLC bought a new position in shares of Perspective Therapeutics in the 1st quarter worth about $6,069,000. 54.66% of the stock is currently owned by institutional investors.
Perspective Therapeutics Stock Down 8.3 %
Shares of CATX stock opened at $12.29 on Friday. Perspective Therapeutics has a one year low of $2.05 and a one year high of $19.05. The company has a quick ratio of 12.98, a current ratio of 12.98 and a debt-to-equity ratio of 0.01. The stock’s 50 day moving average is $12.15.
Perspective Therapeutics (NYSE:CATX – Get Free Report) last issued its quarterly earnings results on Wednesday, May 15th. The company reported ($0.20) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.10. The company had revenue of $0.33 million for the quarter. Equities analysts predict that Perspective Therapeutics will post -1.02 earnings per share for the current year.
About Perspective Therapeutics
Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.
Read More
- Five stocks we like better than Perspective Therapeutics
- Basic Materials Stocks Investing
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
- Where to Find Earnings Call Transcripts
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- Why Are Stock Sectors Important to Successful Investing?
- Intel Loses a Quarter of Its Value After Horrible Earnings Report
Receive News & Ratings for Perspective Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perspective Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.